Optomed
3.95
EUR
+0.64 %
OPTOMED
NASDAQ Helsinki
Medical Equipment & Services
Health Care
5,331 following
+0.64%
-8.14%
-20.52%
-36.29%
+6.33%
+25.8%
-64.41%
-
-13.76%
www.optomed.com/investors
Optomed is a medical technology company. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that is resold under different brands. The company operates worldwide, with the largest presence in the Nordic market. The customers consist of research institutes and hospitals. Optomed is headquartered in Oulu.
P/E (adj.) (24e)
-16.27
EV/EBIT (adj.) (24e)
-15.11
P/B (24e)
3.23
Dividend yield-% (24e)
-
Target price
5.50 EUR
Recommendation
Buy
Updated
18.11.2024
NASDAQ Helsinki
OPTOMED
Daily low / high price
3.935 / 4.08
EUR
Market cap
77.79M EUR
Turnover
185.53K EUR
Volume
47K
Business risk
Valuation risk
Current
Previous
Analyst
Juha Kinnunen
Analyst
Latest videos
Financial calendar
Annual report
2025-02-13
Interim report
2025-05-06
Interim report
2025-08-07
Interim report
2025-11-06
Income statement
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.0 | 14.9 | 14.7 | 15.1 | 15.0 | 20.2 | 27.5 | 34.7 |
| growth-% | -13.1 % | 14.1 % | -1.3 % | 3.0 % | -0.4 % | 34.5 % | 35.7 % | 26.3 % |
| EBITDA | -0.7 | -2.0 | -2.0 | -1.8 | -2.2 | -1.1 | 4.0 | 8.6 |
| EBIT (adj.) | -2.9 | -4.8 | -5.1 | -3.7 | -4.6 | -4.2 | -1.5 | 2.1 |
| EBIT | -2.9 | -4.8 | -5.1 | -4.0 | -4.6 | -4.2 | -1.5 | 2.1 |
| Profit before taxes | -3.2 | -4.3 | -5.6 | -4.5 | -4.7 | -4.5 | -1.7 | 1.8 |
| Net income | -3.2 | -4.2 | -5.5 | -4.4 | -4.7 | -4.5 | -1.7 | 1.8 |
| EPS (adj.) | -0.24 | -0.31 | -0.38 | -0.25 | -0.24 | -0.23 | -0.09 | 0.09 |
| growth-% | ||||||||
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| EBITDA-% | -5.6 % | -13.5 % | -13.3 % | -11.8 % | -14.5 % | -5.2 % | 14.7 % | 24.8 % |
| EBIT-% (adj.) | -22.3 % | -32.2 % | -34.8 % | -24.3 % | -30.8 % | -21.0 % | -5.4 % | 6.1 % |
| EBIT-% | -22.3 % | -32.2 % | -34.8 % | -26.3 % | -30.8 % | -21.0 % | -5.4 % | 6.1 % |
| ROE | -14.9 % | -22.9 % | -29.3 % | -21.8 % | -21.3 % | -21.2 % | -9.4 % | 9.9 % |
| ROI | -9.8 % | -18.9 % | -20.5 % | -15.5 % | -17.5 % | -16.0 % | -5.7 % | 8.3 % |
Valuation
| 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
|---|---|---|---|---|---|---|---|---|
| Share price (EUR) | 7.10 | 9.80 | 3.75 | 3.72 | 3.95 | 3.95 | 3.95 | 3.95 |
| Shares | 13.3 | 13.6 | 16.2 | 17.8 | 19.3 | 19.3 | 19.3 | 19.3 |
| Market cap | 94.2 | 133.1 | 60.5 | 66.1 | 76.2 | 76.2 | 76.2 | 76.2 |
| Enterprise value | 90.1 | 133.3 | 57.3 | 62.4 | 70.0 | 77.0 | 80.0 | 79.6 |
| EV/S | 6.9 | 9.0 | 3.9 | 4.1 | 4.7 | 3.8 | 2.9 | 2.3 |
| EV/EBITDA | - | - | - | - | - | - | 19.8 | 9.3 |
| EV/EBIT (adj.) | - | - | - | - | - | - | - | 37.4 |
| EV/EBIT | - | - | - | - | - | - | - | 37.4 |
| P/E (adj.) | - | - | - | - | - | - | - | 42.4 |
| P/E | - | - | - | - | - | - | - | 42.4 |
| P/B | 4.7 | 7.8 | 3.0 | 3.2 | 3.2 | 4.0 | 4.4 | 4.0 |
| P/S | 7.2 | 9.0 | 4.1 | 4.4 | 5.1 | 3.8 | 2.8 | 2.2 |
| Dividend yield | ||||||||
| Equity ratio | 64.6 % | 58.8 % | 65.0 % | 70.0 % | 72.3 % | 63.1 % | 52.5 % | 50.2 % |
| Gearing ratio | -20.4 % | 1.2 % | -16.0 % | -18.5 % | -26.2 % | 4.3 % | 21.9 % | 17.7 % |
Quarter data
| Q4/23 | 2023 | Q1/24 | Q2/24 | Q3/24 | Q4/24e | 2024e | Q1/25e | Q2/25e | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7 | 15.1 | 3.3 | 3.5 | 3.1 | 5.1 | 15.0 | 4.1 | 4.8 |
| EBITDA | -0.8 | -1.8 | -0.6 | -1.2 | -0.8 | 0.5 | -2.2 | -0.4 | -0.2 |
| EBIT | -1.3 | -4.0 | -1.2 | -1.9 | -1.4 | -0.2 | -4.6 | -1.1 | -1.0 |
| Profit before taxes | -1.5 | -4.5 | -1.1 | -1.8 | -1.6 | -0.2 | -4.7 | -1.2 | -1.1 |
| Net income | -1.5 | -4.4 | -1.1 | -1.8 | -1.6 | -0.2 | -4.7 | -1.2 | -1.1 |
ShowingAll content types
Optomed Oyj: Share subscriptions based on stock options 2018C
Optomed Oyj: Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools